Sarepta Therapeutics Inc (SRPT)
123.24
-0.05
(-0.04%)
USD |
NASDAQ |
Nov 04, 13:00
Sarepta Therapeutics Enterprise Value: 11.52B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 11.52B |
| October 31, 2024 | 11.78B |
| October 30, 2024 | 11.95B |
| October 29, 2024 | 12.18B |
| October 28, 2024 | 12.19B |
| October 25, 2024 | 12.27B |
| October 24, 2024 | 12.36B |
| October 23, 2024 | 12.15B |
| October 22, 2024 | 12.01B |
| October 21, 2024 | 11.91B |
| October 18, 2024 | 11.88B |
| October 17, 2024 | 11.62B |
| October 16, 2024 | 11.77B |
| October 15, 2024 | 11.57B |
| October 14, 2024 | 11.63B |
| October 11, 2024 | 11.64B |
| October 10, 2024 | 11.44B |
| October 09, 2024 | 11.02B |
| October 08, 2024 | 11.18B |
| October 07, 2024 | 11.00B |
| October 04, 2024 | 11.25B |
| October 03, 2024 | 11.09B |
| October 02, 2024 | 11.45B |
| October 01, 2024 | 11.43B |
| September 30, 2024 | 11.68B |
| Date | Value |
|---|---|
| September 27, 2024 | 11.64B |
| September 26, 2024 | 11.67B |
| September 25, 2024 | 11.65B |
| September 24, 2024 | 11.73B |
| September 23, 2024 | 11.67B |
| September 20, 2024 | 11.90B |
| September 19, 2024 | 11.89B |
| September 18, 2024 | 11.69B |
| September 17, 2024 | 11.75B |
| September 16, 2024 | 11.62B |
| September 13, 2024 | 11.65B |
| September 12, 2024 | 11.72B |
| September 11, 2024 | 12.01B |
| September 10, 2024 | 11.87B |
| September 09, 2024 | 11.94B |
| September 06, 2024 | 12.06B |
| September 05, 2024 | 12.52B |
| September 04, 2024 | 12.62B |
| September 03, 2024 | 12.65B |
| August 30, 2024 | 12.71B |
| August 29, 2024 | 12.85B |
| August 28, 2024 | 13.01B |
| August 27, 2024 | 13.18B |
| August 26, 2024 | 13.15B |
| August 23, 2024 | 13.17B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.483B
Minimum
Jan 19 2022
15.34B
Maximum
Jun 24 2024
8.890B
Average
9.221B
Median
Aug 24 2022
Enterprise Value Benchmarks
| Regenxbio Inc | 144.07M |
| Catalyst Pharmaceuticals Inc | 2.222B |
| Vertex Pharmaceuticals Inc | 115.80B |
| Entrada Therapeutics Inc | 184.97M |
| Edgewise Therapeutics Inc | 2.677B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 6.46M |
| Revenue (Quarterly) | 362.93M |
| Total Expenses (Quarterly) | 363.63M |
| EPS Diluted (Quarterly) | 0.07 |
| Gross Profit Margin (Quarterly) | 87.73% |
| Profit Margin (Quarterly) | 1.78% |
| Earnings Yield | 0.60% |
| Operating Earnings Yield | 0.32% |
| Normalized Earnings Yield | 0.8996 |